English
Back
Open Account

先瑞達醫療-B開啟招股,你會參與認購嗎?

$ACOTEC-B (06669.HK)$ 於8月12日-8月17日招股,每股發行價22.2-23.8港元,每手1000股,最小認購金額24039.83港元,預計將於8月24日上市。 先瑞達醫療是一家領先的中國創新醫療器械企業,此次在港上市你會參與認購嗎?快來曬出你的認購單吧! Show More
於8月12日-8月17日招股,每股發行價22.2-23.8港元,每手1000股,最小認購金額24039.83港元,預計將於8月24日上市。
先瑞達醫療是一家領先的中國創新醫療器械企業,此次在港上市你會參與認購嗎?快來曬出你的認購單吧!
Views
257K
Posts
98
Join topic
Latest
Hot
    Regarding the understanding of technical analysis
    Technical analysis is a skill that sets aside fundamental analysis to use market sentiment for new stock trading. This approach is often used during market uptrends. The author prefers to use technical analysis for new stock trading, being able to handle both hot and cold new stocks. The advantages are higher chances of successful lotteries and easy purchases. The disadvantages include the risk of price drops, even significant ones, as well as the risk of first-day price drops or dark trading, making it challenging for long-term holding.
    Fundamental analysis focuses on new stocks with excellent fundamentals. The benefits include predictable profits or substantial profits. The drawbacks are lower chances of successful lotteries due to intense competition and potential loss of interest. Combining both methods, the author believes that each has its pros and cons, which can be balanced.
    Let's now carefully analyze the technical support for investing in Xianruida. Currently, the market sentiment is declining, so it definitely does not support new stock trading. Looking at the recent performance of new listings, there are no highly profitable stocks. The only recent new listing, Li Auto, experienced a price drop. In this scenario, why would the author still choose Xianruida? It's because the author has noticed some subtle details.
    Basic fundamental analysis is needed here. Xianruida leads in a specific niche market, focusing on two products. One product has captured a market share of 86.9%, while the other is also a market leader. See the chart for details.
    13 cornerstone investors took 50% of the shares, mostly domestic funds and unknown cornerstone investors, without the presence of foreign star cornerstone investors, which is the first point of controversy. The post-valuation is around 7 billion, with a 15% increase from the last round of financing, which is indeed a very conscientious valuation increase compared to the previous medical stocks that usually doubled or tripled in valuation after issuance.
    change your mindset and use technology to overlay fundamental analysis in the discussion of Xianruida
    change your mindset and use technology to overlay fundamental analysis in the discussion of Xianruida
    change your mindset and use technology to overlay fundamental analysis in the discussion of Xianruida
    +3
    41
    56
Unlock Pro Investors’ Money-Making Secrets
Join Futubull Community! Now Connect Directly with Top Investors & Public Company Executives
Unlock it Now
Related Stocks
No Data